Side-by-side comparison
Biogen vs Eli Lilly and
As of Sep 25, 2026, P/E is 24.5x for Biogen vs 39.7x for Eli Lilly and; P/S is 3.4x for Biogen vs 14.0x for Eli Lilly and; revenue growth is 1.2% for Biogen vs 49.6% for Eli Lilly and; net margin is 13.8% for Biogen vs 33.5% for Eli Lilly and.
Key metrics
| Metric | BIIB | LLY |
|---|---|---|
| Price | $227.60 | $1,183.46 |
| Market cap | $33.6B | $1.11T |
| P/E | 24.5x (#1) | 39.7x (#2) |
| P/S | 3.4x (#1) | 14.0x (#2) |
| Revenue growth | 1.2% (#2) | 49.6% (#1) |
| Operating margin | 24.9% (#1) | — |
| Net margin | 13.8% (#2) | 33.5% (#1) |
| Debt / equity | 0.34 (#1) | 1.41 (#2) |
| 1-year return | +65.7% (#1) | +63.3% (#2) |
| Research score | 67/100 (#2) | 69/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Biogen Inc. (BIIB) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General